Daubert Ruling Fuels Thimerosal Debate

By Robert Ambrogi Esq
A federal court ruling excluding all expert testimony that the drug-preservative thimerosal caused a minor child's autism is likely to have repercussions well beyond the case in which it came.

In Winston-Salem, N.C., U.S. District Judge James A. Beaty Jr. dismissed a lawsuit against the manufacturer of the drug RhoGAM. The suit alleged that thimerosal in the drug caused the minor plaintiff's autism. The judge issued the dismissal after he granted a defense motion to exclude all expert testimony drawing a link between thimerosal and autism.

"[W]ithout [the expert's] testimony, Plaintiffs are unable to meet their burden to demonstrate that the thimerosal in Defendant's RhoGAM product caused [Plaintiff's] autism, a result that leads directly to the failure of all of Plaintiffs' claims," Beaty wrote.

The ruling comes as nearly 5,000 claims await disposition in an omnibus proceeding pending before the U.S. Court of Federal Claims under the National Vaccine Injury Compensation Program. The claims allege that thimerosal in childhood vaccines is the cause of claimants' autism disorders.

Judge Beaty acknowledged the significance of his ruling in light of these cases, but said, "[T]his opinion does not determine that future plaintiffs with autistic children will never be able to establish causation in similar cases. However, what it does determine is that, at this point in time, Plaintiffs have failed to present sufficient evidence from which a jury could conclude the thimerosal in RhoGAM caused [plaintiff's] autism."

The decision to exclude all expert testimony came after a three-day Daubert hearing. The hearing focused on the testimony of Dr. Mark Geier, the leading proponent of the thimerosal-autism link and an expert witness in many of the vaccine cases.

The court noted that the bulk of Dr. Geier's testimony was "not based upon his own research, but instead upon a review of the relevant literature." But the literature he relied on, the court went on to conclude, "does not add up to the opinion and conclusion that Dr. Geier is offering."

Given this, Judge Beaty concluded that the plaintiffs had failed to establish under Federal Rule of Evidence 702 that Dr. Geier should be allowed to testify concerning the general question of whether exposure to thimerosal in RhoGAM could cause autism.

"Time and additional well-reasoned research may yet bring much needed light to the difficult question that this case poses for Plaintiffs and many others similarly situated, but no such answers can be reached on the record currently before the Court," Judge Beaty wrote.

"Accordingly, notwithstanding the valiant effort by Plaintiffs in this case, Defendant’s Motion for Summary Judgment must be allowed and this case must be dismissed with prejudice."

The case is Doe v. Ortho-Clinical Diagnostics Inc., Case No. 1:03CV00669 (M.D. N.C. July 6, 2006).


Robert Ambrogi Esq

We are proud to partner with an author of Bob’s caliber to provide exclusive articles for our legal clients and leading industry experts. Robert J. Ambrogi is a news media veteran and the only person ever to hold the top editorial positions at the two leading national U.S. legal newspapers, the National Law Journal and Lawyers Weekly USA. He is currently a Massachusetts lawyer who represents clients at the intersection of law, media and technology. He is also internationally known for his writing and blogging about the Internet and technology. Media and Technology Law Bob represents a range of businesses and individuals, concentrating in print and electronic media companies and the editorial, sales, marketing and technology professionals who work in them. He also counsels businesses and individuals in employment matters. Arbitration and Mediation An established professional in alternative dispute resolution, Bob has been an arbitrator since 1994, focusing on labor and employment and securities disputes. A mediator in a range of civil disputes, Bob completed the training required by Massachusetts law to protect confidentiality.

Get the best expert

Fill out the form and one of our representatives will be in touch with you shortly. Or, you can call or email us directly.